Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$131.04 +0.3%	$123.75	$110.04 ▼ $238.00	$19.20B	0.14	1.43 million shs	1.11 million shs
BMY Bristol-Myers Squibb	$48.65 -2.2%	$48.71	$39.35 ▼ $63.33	$99.01B	0.38	13.00 million shs	14.97 million shs
PFE Pfizer	$24.40 -0.6%	$23.06	$20.92 ▼ $31.54	$138.71B	0.57	41.18 million shs	35.08 million shs
SNY Sanofi	$49.41 -0.5%	$51.49	$45.80 ▼ $60.12	$121.18B	0.5	2.38 million shs	1.95 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	-1.86%	+4.03%	-8.98%	-43.61%
BMY Bristol-Myers Squibb	0.00%	+2.65%	+6.28%	-17.25%	+20.64%
PFE Pfizer	0.00%	+4.93%	+7.39%	-5.97%	-10.97%
SNY Sanofi	0.00%	-1.59%	-3.89%	-15.70%	+7.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.7372 of 5 stars	4.2	3.0	0.0	3.7	3.1	1.7	1.9
BMY Bristol-Myers Squibb	4.8103 of 5 stars	3.2	5.0	4.2	4.0	2.9	3.3	0.0
PFE Pfizer	4.9768 of 5 stars	3.3	4.0	4.2	4.3	2.8	1.7	3.1
SNY Sanofi	3.4244 of 5 stars	2.6	3.0	2.5	0.0	2.2	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$188.19	43.61% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$58.00	19.22% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	19.55% Upside
SNY Sanofi	3.13	Buy	$61.50	24.47% Upside

Current Analyst Ratings Breakdown

Latest SNY, PFE, BMY, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/3/2025	SNY Sanofi	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$56.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/5/2025	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$185.00 ➝ $175.00
5/2/2025	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$205.00
5/2/2025	BIIB Biogen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$217.00 ➝ $205.00
5/2/2025	BIIB Biogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$265.00 ➝ $220.00
5/2/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$241.00 ➝ $187.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.82B	1.96	$21.52 per share	6.09	$114.71 per share	1.14
BMY Bristol-Myers Squibb	$47.64B	2.08	$5.13 per share	9.48	$8.08 per share	6.02
PFE Pfizer	$62.46B	2.22	$3.82 per share	6.38	$15.81 per share	1.54
SNY Sanofi	$45.17B	2.68	$4.86 per share	10.16	$33.20 per share	1.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	11.71	7.94	1.51	16.87%	14.98%	8.76%	7/30/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	$2.67	N/A	7.99	2.07	-18.53%	13.93%	2.46%	7/31/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.30	8.05	0.64	12.62%	19.47%	8.09%	7/29/2025 (Estimated)
SNY Sanofi	$6.02B	$2.80	19.84	10.40	1.01	12.77%	25.61%	14.72%	7/24/2025 (Estimated)

Latest SNY, PFE, BMY, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol-Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	SNY Sanofi	$0.90	$0.94	+$0.04	$0.80	$9.79 billion	$10.41 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMY Bristol-Myers Squibb	$2.48	5.10%	N/A	92.88%	17 Years
PFE Pfizer	$1.72	7.05%	N/A	124.64%	16 Years
SNY Sanofi	$1.59	3.22%	N/A	56.79%	N/A

Latest SNY, PFE, BMY, and BIIB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	SNY Sanofi	annual	$2.0369	3.1%	5/9/2025	5/9/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
BMY Bristol-Myers Squibb	2.90	1.25	1.15
PFE Pfizer	0.63	1.00	0.73
SNY Sanofi	0.15	1.46	1.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
BMY Bristol-Myers Squibb	76.41%
PFE Pfizer	68.36%
SNY Sanofi	14.04%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
BMY Bristol-Myers Squibb	0.09%
PFE Pfizer	0.06%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.53 million	146.14 million	Optionable
BMY Bristol-Myers Squibb	34,300	2.04 billion	2.03 billion	Optionable
PFE Pfizer	83,000	5.69 billion	5.66 billion	Optionable
SNY Sanofi	91,600	2.45 billion	2.51 billion	Optionable

SNY, PFE, BMY, and BIIB Headlines

Recent News About These Companies

SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm

June 16 at 7:03 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 16 at 2:20 PM | accessnewswire.com

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

June 16 at 10:11 AM | zacks.com

Sanofi: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented ...

June 16 at 8:21 AM | finanznachrichten.de

Dynamic Advisor Solutions LLC Invests $3.10 Million in Sanofi (NASDAQ:SNY)

June 16 at 4:39 AM | marketbeat.com

Sanofi (NASDAQ:SNY) Stake Lifted by SG Americas Securities LLC

June 16 at 3:48 AM | marketbeat.com

Zacks Research Issues Positive Estimate for Sanofi Earnings

June 16 at 1:35 AM | marketbeat.com

Regeneron and Sanofi Announce Dupixent Outperformance over Xolair in Phase 4 EVEREST Trial Results for CRSwNP and Asthma

June 15 at 11:42 AM | quiverquant.com

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

June 15 at 11:22 AM | globenewswire.com

BayBridge Capital Group LLC Buys Shares of 25,269 Sanofi (NASDAQ:SNY)

June 15 at 7:43 AM | marketbeat.com

Sound Income Strategies LLC Buys 6,073 Shares of Sanofi (NASDAQ:SNY)

June 15 at 7:21 AM | marketbeat.com

Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target

June 15 at 6:43 AM | insidermonkey.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 13 at 10:30 AM | accessnewswire.com

Sanofi (NASDAQ:SNY) Shares Bought by Willis Investment Counsel

June 13 at 6:11 AM | marketbeat.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (SNY)

June 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 12, 2025 | prnewswire.com

Sanofi (NASDAQ:SNY) Shares Purchased by Baker Ellis Asset Management LLC

June 11, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 11, 2025 | accessnewswire.com

Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 10, 2025 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 10, 2025 | globenewswire.com

Merck’s RSV shot for infants cleared in U.S., challenging Sanofi/Astra’s dominance

June 10, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
By Jeffrey Neal Johnson | May 23, 2025
View Pfizer's 7.5% Dividend: Income Haven or House of Cards?

SNY, PFE, BMY, and BIIB Company Descriptions

Biogen NASDAQ:BIIB

$131.04 +0.39 (+0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$130.92 -0.13 (-0.10%)

As of 07:43 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Bristol-Myers Squibb NYSE:BMY

$48.65 -1.10 (-2.21%)

Closing price 03:59 PM Eastern

Extended Trading

$48.72 +0.07 (+0.15%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Pfizer NYSE:PFE

$24.40 -0.14 (-0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$24.38 -0.02 (-0.07%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi NASDAQ:SNY

$49.41 -0.26 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$49.50 +0.09 (+0.18%)

As of 07:53 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time